Protalix Signs $280m Agreement With Brazilian Health Agency for Supply of Gaucher Disease Medication

The seven-year agreement could make Protalix and Pfizer, it's partner in international commercialization, the largest suppliers of Gaucher medication in Brazil.

Protalix Biotherapeutics, the Carmiel-based pharmaceutical firm, announced Wednesday that it had entered into a seven-year supply agreement with an affiliate of Brazil's Health Ministry to supply a minimum of $280 million worth of Uplyso, the company's drug treatment for Gaucher disease.